JAK1 and rheumatoid arthritis: The 15 mg once daily (QD) dose of upadacitinib, having shown superiority to adalimumab in treating RA, was approved by the FDA, making upadacitinib the first ‘JAK1-selective’ jakinib to be approved [27].